Arcus Biosciences, Inc. RCUS 深 沪
等待开盘 06-26 09:30:00 美东时间
30.25
+1.440
+5.00%
华盛通- 最 高31.44
- 今 开28.60
- 成交量 223.83万股
- 最 低 24.59
- 昨 收 28.81
- 总市值 216.95万
- 52周最高 31.44
- 市盈率 静 42.36
- 换手率 3120.91%
- 52周最低 8.03
- 委 比 94.08%
- 总股本 7.17万
- 历史最高 49.10
- 量 比 1.31
- 振 幅 23.78%
- 历史最低 6.30
- 每 手 1
- 风险率 5.85%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug
Arcus ends its Phase 3 STAR-221 trial after a futility review and shifts R&D toward casdatifan, supported by strong early RCC data and key 2026 milestones.
2025-12-13 02:35
Arcus Biosciences Discontinues Phase 3 STAR-221 Study With Gilead Following IDMC Futility Recommendation
The Phase 3 STAR-221 study evaluating a domvanalimab-based combination in upper gastrointestinal cancers will be discontinued due to futilityArcus is continuing to expand its development program for casdatifan, a
2025-12-12 21:33
Arcus Biosciences Gets Up to $250 Million Term Loan Facility From Hercules Capital
05:18 PM EDT, 08/27/2024 (MT Newswires) -- Arcus Biosciences (RCUS) said late Tuesday it secured a term loan facility of up to $250 million from Hercules Capital (HTGC). The loan matures in five years and can be extended to six years upon the initiation of phase 3 trials for casdatifan and quemliclu...
2024-08-28 05:18
